Venu Bathini is an Oncology physician affiliated with UMass Memorial Health Care. OpenAlex indexes 31 publications with 498 citations (h-index 9); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
571 Union Ave Ste 202
Framingham, MA 017025829
Telephone
508-665-6261Provider last certified this registry record 26 Oct 2023.
Clinical trials
- A Trial of Chemo & Radiation Therapy for Pancreatic Cancer
Sponsor: University of Massachusetts, Worcester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Dendreon Pharmaceuticals LLCProgram year20252 payments
- PFIZER INC.Program year20255 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
87.7%Iron, parenteral preparations87.6%Ferric carboxymaltose100%Part B, office-administered≥49 patientsFactor Xa inhibitor0.1%Eliquis78%Xarelto22%Part D<11 patientsMusculoskeletal
10.3%RANK Ligand Inhibitor10.2%Denosumab100%Part B, office-administered≥68 patientsBisphosphonate0.1%Zoledronic acid100%Part B, office-administered≥18 patientsMetabolism & gastrointestinal
0.9%Serotonin-3 Receptor Antagonist0.9%Ondansetron hydrochloride96%Ondansetron Odt4%Part D + Part B≥27 patientsProton pump inhibitor0%Pantoprazole Sodium65%Omeprazole35%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Utility of HNF-1B and a panel of lineage-specific biomarkers to optimize the diagnosis of pancreatic ductal adenocarcinoma.
PubMed
2021 - Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
The Lancet. Gastroenterology & hepatology
2020 - Metastatic Signet Ring Cell Carcinoma of the Ampulla of Vater with an Unusually Prolonged Survival
Journal of Gastrointestinal Cancer
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Aurigemma, MD
UMass Memorial Health Care
Richard Irwin, MD
UMass Memorial Health Care
Craig Lilly, MD
UMass Memorial Health Care
David Keefe, MD
UMass Memorial Health Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”